Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
59
JDOC Quote, Financials, Valuation and Earnings
Last price:
$59.18
Seasonality move
:
-4.23%
Day range:
$58.37 - $58.49
52-week range:
$47.67 - $59.69
Dividend yield:
0.88%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
1.3K
Avg. volume:
601
1-year change:
7.04%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | -- | -- | -- | -- |
|
IXJ
iShares Global Healthcare ETF
|
-- | -- | -- | -- | -- |
|
IYH
iShares US Healthcare ETF
|
-- | -- | -- | -- | -- |
|
MEDX
Horizon Kinetics Medical ETF
|
-- | -- | -- | -- | -- |
|
PPH
VanEck Pharmaceutical ETF
|
-- | -- | -- | -- | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
JDOC
JPMorgan Healthcare Leaders ETF
|
$58.37 | -- | -- | -- | $0.51 | 0.88% | -- |
|
IXJ
iShares Global Healthcare ETF
|
$99.37 | -- | -- | -- | $0.60 | 1.37% | -- |
|
IYH
iShares US Healthcare ETF
|
$65.51 | -- | -- | -- | $0.25 | 1.18% | -- |
|
MEDX
Horizon Kinetics Medical ETF
|
$34.75 | -- | -- | -- | $0.41 | 1.18% | -- |
|
PPH
VanEck Pharmaceutical ETF
|
$108.84 | -- | -- | -- | $0.31 | 1.69% | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
$25.41 | -- | -- | -- | $0.41 | 1.63% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | 0.047 | -- | -- |
|
IXJ
iShares Global Healthcare ETF
|
-- | -0.024 | -- | -- |
|
IYH
iShares US Healthcare ETF
|
-- | -0.054 | -- | -- |
|
MEDX
Horizon Kinetics Medical ETF
|
-- | 0.120 | -- | -- |
|
PPH
VanEck Pharmaceutical ETF
|
-- | 0.069 | -- | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | 0.745 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | -- | -- | -- | -- | -- |
|
IXJ
iShares Global Healthcare ETF
|
-- | -- | -- | -- | -- | -- |
|
IYH
iShares US Healthcare ETF
|
-- | -- | -- | -- | -- | -- |
|
MEDX
Horizon Kinetics Medical ETF
|
-- | -- | -- | -- | -- | -- |
|
PPH
VanEck Pharmaceutical ETF
|
-- | -- | -- | -- | -- | -- |
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- | -- |
JPMorgan Healthcare Leaders ETF vs. Competitors
-
Which has Higher Returns JDOC or IXJ?
iShares Global Healthcare ETF has a net margin of -- compared to JPMorgan Healthcare Leaders ETF's net margin of --. JPMorgan Healthcare Leaders ETF's return on equity of -- beat iShares Global Healthcare ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital JDOCJPMorgan Healthcare Leaders ETF-- -- -- IXJiShares Global Healthcare ETF-- -- -- -
What do Analysts Say About JDOC or IXJ?
JPMorgan Healthcare Leaders ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Global Healthcare ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that JPMorgan Healthcare Leaders ETF has higher upside potential than iShares Global Healthcare ETF, analysts believe JPMorgan Healthcare Leaders ETF is more attractive than iShares Global Healthcare ETF.
Company Buy Ratings Hold Ratings Sell Ratings JDOCJPMorgan Healthcare Leaders ETF0 0 0 IXJiShares Global Healthcare ETF0 0 0 -
Is JDOC or IXJ More Risky?
JPMorgan Healthcare Leaders ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iShares Global Healthcare ETF has a beta of 0.676, suggesting its less volatile than the S&P 500 by 32.433%.
-
Which is a Better Dividend Stock JDOC or IXJ?
JPMorgan Healthcare Leaders ETF has a quarterly dividend of $0.51 per share corresponding to a yield of 0.88%. iShares Global Healthcare ETF offers a yield of 1.37% to investors and pays a quarterly dividend of $0.60 per share. JPMorgan Healthcare Leaders ETF pays -- of its earnings as a dividend. iShares Global Healthcare ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JDOC or IXJ?
JPMorgan Healthcare Leaders ETF quarterly revenues are --, which are smaller than iShares Global Healthcare ETF quarterly revenues of --. JPMorgan Healthcare Leaders ETF's net income of -- is lower than iShares Global Healthcare ETF's net income of --. Notably, JPMorgan Healthcare Leaders ETF's price-to-earnings ratio is -- while iShares Global Healthcare ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for JPMorgan Healthcare Leaders ETF is -- versus -- for iShares Global Healthcare ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JDOCJPMorgan Healthcare Leaders ETF-- -- -- -- IXJiShares Global Healthcare ETF-- -- -- --
-
Which has Higher Returns JDOC or IYH?
iShares US Healthcare ETF has a net margin of -- compared to JPMorgan Healthcare Leaders ETF's net margin of --. JPMorgan Healthcare Leaders ETF's return on equity of -- beat iShares US Healthcare ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital JDOCJPMorgan Healthcare Leaders ETF-- -- -- IYHiShares US Healthcare ETF-- -- -- -
What do Analysts Say About JDOC or IYH?
JPMorgan Healthcare Leaders ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares US Healthcare ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that JPMorgan Healthcare Leaders ETF has higher upside potential than iShares US Healthcare ETF, analysts believe JPMorgan Healthcare Leaders ETF is more attractive than iShares US Healthcare ETF.
Company Buy Ratings Hold Ratings Sell Ratings JDOCJPMorgan Healthcare Leaders ETF0 0 0 IYHiShares US Healthcare ETF0 0 0 -
Is JDOC or IYH More Risky?
JPMorgan Healthcare Leaders ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iShares US Healthcare ETF has a beta of 0.680, suggesting its less volatile than the S&P 500 by 31.972%.
-
Which is a Better Dividend Stock JDOC or IYH?
JPMorgan Healthcare Leaders ETF has a quarterly dividend of $0.51 per share corresponding to a yield of 0.88%. iShares US Healthcare ETF offers a yield of 1.18% to investors and pays a quarterly dividend of $0.25 per share. JPMorgan Healthcare Leaders ETF pays -- of its earnings as a dividend. iShares US Healthcare ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JDOC or IYH?
JPMorgan Healthcare Leaders ETF quarterly revenues are --, which are smaller than iShares US Healthcare ETF quarterly revenues of --. JPMorgan Healthcare Leaders ETF's net income of -- is lower than iShares US Healthcare ETF's net income of --. Notably, JPMorgan Healthcare Leaders ETF's price-to-earnings ratio is -- while iShares US Healthcare ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for JPMorgan Healthcare Leaders ETF is -- versus -- for iShares US Healthcare ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JDOCJPMorgan Healthcare Leaders ETF-- -- -- -- IYHiShares US Healthcare ETF-- -- -- --
-
Which has Higher Returns JDOC or MEDX?
Horizon Kinetics Medical ETF has a net margin of -- compared to JPMorgan Healthcare Leaders ETF's net margin of --. JPMorgan Healthcare Leaders ETF's return on equity of -- beat Horizon Kinetics Medical ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital JDOCJPMorgan Healthcare Leaders ETF-- -- -- MEDXHorizon Kinetics Medical ETF-- -- -- -
What do Analysts Say About JDOC or MEDX?
JPMorgan Healthcare Leaders ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Horizon Kinetics Medical ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that JPMorgan Healthcare Leaders ETF has higher upside potential than Horizon Kinetics Medical ETF, analysts believe JPMorgan Healthcare Leaders ETF is more attractive than Horizon Kinetics Medical ETF.
Company Buy Ratings Hold Ratings Sell Ratings JDOCJPMorgan Healthcare Leaders ETF0 0 0 MEDXHorizon Kinetics Medical ETF0 0 0 -
Is JDOC or MEDX More Risky?
JPMorgan Healthcare Leaders ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Horizon Kinetics Medical ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock JDOC or MEDX?
JPMorgan Healthcare Leaders ETF has a quarterly dividend of $0.51 per share corresponding to a yield of 0.88%. Horizon Kinetics Medical ETF offers a yield of 1.18% to investors and pays a quarterly dividend of $0.41 per share. JPMorgan Healthcare Leaders ETF pays -- of its earnings as a dividend. Horizon Kinetics Medical ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JDOC or MEDX?
JPMorgan Healthcare Leaders ETF quarterly revenues are --, which are smaller than Horizon Kinetics Medical ETF quarterly revenues of --. JPMorgan Healthcare Leaders ETF's net income of -- is lower than Horizon Kinetics Medical ETF's net income of --. Notably, JPMorgan Healthcare Leaders ETF's price-to-earnings ratio is -- while Horizon Kinetics Medical ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for JPMorgan Healthcare Leaders ETF is -- versus -- for Horizon Kinetics Medical ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JDOCJPMorgan Healthcare Leaders ETF-- -- -- -- MEDXHorizon Kinetics Medical ETF-- -- -- --
-
Which has Higher Returns JDOC or PPH?
VanEck Pharmaceutical ETF has a net margin of -- compared to JPMorgan Healthcare Leaders ETF's net margin of --. JPMorgan Healthcare Leaders ETF's return on equity of -- beat VanEck Pharmaceutical ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital JDOCJPMorgan Healthcare Leaders ETF-- -- -- PPHVanEck Pharmaceutical ETF-- -- -- -
What do Analysts Say About JDOC or PPH?
JPMorgan Healthcare Leaders ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand VanEck Pharmaceutical ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that JPMorgan Healthcare Leaders ETF has higher upside potential than VanEck Pharmaceutical ETF, analysts believe JPMorgan Healthcare Leaders ETF is more attractive than VanEck Pharmaceutical ETF.
Company Buy Ratings Hold Ratings Sell Ratings JDOCJPMorgan Healthcare Leaders ETF0 0 0 PPHVanEck Pharmaceutical ETF0 0 0 -
Is JDOC or PPH More Risky?
JPMorgan Healthcare Leaders ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VanEck Pharmaceutical ETF has a beta of 0.560, suggesting its less volatile than the S&P 500 by 44.036%.
-
Which is a Better Dividend Stock JDOC or PPH?
JPMorgan Healthcare Leaders ETF has a quarterly dividend of $0.51 per share corresponding to a yield of 0.88%. VanEck Pharmaceutical ETF offers a yield of 1.69% to investors and pays a quarterly dividend of $0.31 per share. JPMorgan Healthcare Leaders ETF pays -- of its earnings as a dividend. VanEck Pharmaceutical ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JDOC or PPH?
JPMorgan Healthcare Leaders ETF quarterly revenues are --, which are smaller than VanEck Pharmaceutical ETF quarterly revenues of --. JPMorgan Healthcare Leaders ETF's net income of -- is lower than VanEck Pharmaceutical ETF's net income of --. Notably, JPMorgan Healthcare Leaders ETF's price-to-earnings ratio is -- while VanEck Pharmaceutical ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for JPMorgan Healthcare Leaders ETF is -- versus -- for VanEck Pharmaceutical ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JDOCJPMorgan Healthcare Leaders ETF-- -- -- -- PPHVanEck Pharmaceutical ETF-- -- -- --
-
Which has Higher Returns JDOC or THNR?
Amplify Weight Loss Drug & Treatment ETF has a net margin of -- compared to JPMorgan Healthcare Leaders ETF's net margin of --. JPMorgan Healthcare Leaders ETF's return on equity of -- beat Amplify Weight Loss Drug & Treatment ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital JDOCJPMorgan Healthcare Leaders ETF-- -- -- THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -
What do Analysts Say About JDOC or THNR?
JPMorgan Healthcare Leaders ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Amplify Weight Loss Drug & Treatment ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that JPMorgan Healthcare Leaders ETF has higher upside potential than Amplify Weight Loss Drug & Treatment ETF, analysts believe JPMorgan Healthcare Leaders ETF is more attractive than Amplify Weight Loss Drug & Treatment ETF.
Company Buy Ratings Hold Ratings Sell Ratings JDOCJPMorgan Healthcare Leaders ETF0 0 0 THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 -
Is JDOC or THNR More Risky?
JPMorgan Healthcare Leaders ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock JDOC or THNR?
JPMorgan Healthcare Leaders ETF has a quarterly dividend of $0.51 per share corresponding to a yield of 0.88%. Amplify Weight Loss Drug & Treatment ETF offers a yield of 1.63% to investors and pays a quarterly dividend of $0.41 per share. JPMorgan Healthcare Leaders ETF pays -- of its earnings as a dividend. Amplify Weight Loss Drug & Treatment ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JDOC or THNR?
JPMorgan Healthcare Leaders ETF quarterly revenues are --, which are smaller than Amplify Weight Loss Drug & Treatment ETF quarterly revenues of --. JPMorgan Healthcare Leaders ETF's net income of -- is lower than Amplify Weight Loss Drug & Treatment ETF's net income of --. Notably, JPMorgan Healthcare Leaders ETF's price-to-earnings ratio is -- while Amplify Weight Loss Drug & Treatment ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for JPMorgan Healthcare Leaders ETF is -- versus -- for Amplify Weight Loss Drug & Treatment ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JDOCJPMorgan Healthcare Leaders ETF-- -- -- -- THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
93
NBTX alert for Mar 5
Nanobiotix SA [NBTX] is down 7.15% over the past day.
Sell
45
MRNA alert for Mar 5
Moderna, Inc. [MRNA] is down 6.83% over the past day.
Buy
77
SSRM alert for Mar 5
SSR Mining, Inc. [SSRM] is down 6.13% over the past day.
